≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Disorder of bilirubin metabolism, other/unspecified

DOID Endpoint Browser PheWeb

E4_PORBILIRNAS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E80.6, E80.7
  • Hospital discharge: ICD-9 — 2774X
  • Cause of death: ICD-10 — E80.6, E80.7
  • Cause of death: ICD-9 — 2774X

2 out of 7 registries used, show all original rules.

58

4. Check minimum number of events

None

58

5. Include endpoints

None

58

6. Filter based on genotype QC (FinnGen only)

57

Control definitions (FinnGen only)

Control exclude
E4_METABOLIA

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 486 210 276
Only index persons 423 185 238
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population - 43.10 42.16
Only index persons 42.70 45.65 40.40

-FinnGen-

Key figures

All Female Male
Number of individuals 57 25 32
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 58.50 62.50 55.38

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
58
Matched controls
580
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E80.7
ICD-10 Finland
Disorder of bilirubin metabolism, unspecified
+∞
39.0
33
*
E80.6
ICD-10 Finland
Other disorders of bilirubin metabolism
+∞
26.0
23
*
E80.4
ICD-10 Finland
Gilbert syndrome
+∞
8.5
8
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
1.4e-01
1.4e+00
3.5e+00
1.0e+50
3.0e+00
—
—
cases:23.64%
controls:21.27%
cases:38.18%
controls:13.27%
cases:30.91%
controls:1.27%
cases:12.73%
controls:0.00%
cases:23.64%
controls:1.46%
—
—
—
—
13
117
42
433
21
73
34
477
17
7
38
543
7
0
48
550
13
8
42
541
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
4.5e-01
1.0e+00
2.2e+00
—
2.5e+00
—
—
cases:18.18%
controls:12.36%
cases:16.36%
controls:6.55%
cases:18.18%
controls:2.36%
—
—
cases:18.18%
controls:1.82%
—
—
—
—
10
68
45
482
9
36
46
514
10
13
45
537
—
10
10
45
539
—
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
-2.1e-01
1.4e+00
3.2e+00
—
—
—
—
cases:10.91%
controls:13.09%
cases:20.00%
controls:6.00%
cases:21.82%
controls:1.09%
—
—
—
—
—
—
—
—
6
72
49
478
11
33
44
517
12
6
43
544
—
—
—
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
-2.1e-01
9.4e-01
2.4e+00
—
2.1e+00
—
—
cases:12.73%
controls:15.27%
cases:21.82%
controls:9.82%
cases:12.73%
controls:1.27%
—
—
cases:14.55%
controls:2.00%
—
—
—
—
7
84
48
466
12
54
43
496
7
7
48
543
—
8
11
47
538
—
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.1e-01
7.6e-01
2.2e+00
1.0e+50
2.0e+00
—
—
cases:45.45%
controls:40.36%
cases:47.27%
controls:29.64%
cases:30.91%
controls:4.91%
cases:14.55%
controls:0.00%
cases:23.64%
controls:3.83%
—
—
—
—
25
222
30
328
26
163
29
387
17
27
38
523
8
0
47
550
13
21
42
528
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.6e-01
5.8e-01
2.1e+00
1.0e+50
1.8e+00
—
—
cases:40.00%
controls:36.18%
cases:36.36%
controls:24.18%
cases:20.00%
controls:3.09%
cases:18.18%
controls:0.00%
cases:20.00%
controls:4.01%
—
—
—
—
22
199
33
351
20
133
35
417
11
17
44
533
10
0
45
550
11
22
44
527
—
—
Case Management Agency
251B00000X [38004193]
5.6e-01
1.3e-01
6.0e-01
3.8e+00
8.5e-01
—
—
cases:80.00%
controls:69.45%
cases:67.27%
controls:64.36%
cases:38.18%
controls:25.27%
cases:40.00%
controls:1.45%
cases:41.82%
controls:23.50%
—
—
—
—
44
382
11
168
37
354
18
196
21
139
34
411
22
8
33
542
23
129
32
420
—
—
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.0e-01
3.2e-01
1.8e+00
1.0e+50
2.0e+00
—
—
cases:34.55%
controls:30.18%
cases:32.73%
controls:26.18%
cases:23.64%
controls:4.73%
cases:12.73%
controls:0.00%
cases:25.45%
controls:4.55%
—
—
—
—
19
166
36
384
18
144
37
406
13
26
42
524
7
0
48
550
14
25
41
524
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.6e-01
4.5e-01
1.8e+00
1.0e+50
1.9e+00
—
—
cases:34.55%
controls:28.91%
cases:34.55%
controls:25.27%
cases:21.82%
controls:4.36%
cases:14.55%
controls:0.00%
cases:20.00%
controls:3.64%
—
—
—
—
19
159
36
391
19
139
36
411
12
24
43
526
8
0
47
550
11
20
44
529
—
—
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
-2.6e-01
1.3e+00
—
—
2.2e+00
—
—
cases:9.09%
controls:11.45%
cases:21.82%
controls:7.09%
—
—
—
—
cases:10.91%
controls:1.28%
—
—
—
—
5
63
50
487
12
39
43
511
—
—
6
7
49
542
—
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
-2.6e-01
1.3e+00
—
—
2.1e+00
—
—
cases:9.09%
controls:11.45%
cases:21.82%
controls:7.09%
—
—
—
—
cases:10.91%
controls:1.46%
—
—
—
—
5
63
50
487
12
39
43
511
—
—
6
8
49
541
—
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
8.0e-02
4.4e-01
1.8e+00
1.0e+50
1.5e+00
—
—
cases:47.27%
controls:45.27%
cases:50.91%
controls:40.00%
cases:30.91%
controls:6.73%
cases:18.18%
controls:0.00%
cases:29.09%
controls:8.01%
—
—
—
—
26
249
29
301
28
220
27
330
17
37
38
513
10
0
45
550
16
44
39
505
—
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
7.3e-02
4.3e-01
1.8e+00
1.0e+50
1.5e+00
—
—
cases:47.27%
controls:45.45%
cases:50.91%
controls:40.18%
cases:30.91%
controls:6.73%
cases:18.18%
controls:0.00%
cases:29.09%
controls:8.01%
—
—
—
—
26
250
29
300
28
221
27
329
17
37
38
513
10
0
45
550
16
44
39
505
—
—
Platelets [#/volume] in Blood
26515-7 [3007461]
8.0e-02
4.4e-01
1.8e+00
1.0e+50
1.5e+00
—
—
cases:47.27%
controls:45.27%
cases:50.91%
controls:40.00%
cases:30.91%
controls:6.73%
cases:18.18%
controls:0.00%
cases:29.09%
controls:8.01%
—
—
—
—
26
249
29
301
28
220
27
330
17
37
38
513
10
0
45
550
16
44
39
505
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
7.3e-02
4.4e-01
1.8e+00
1.0e+50
1.5e+00
—
—
cases:47.27%
controls:45.45%
cases:50.91%
controls:40.00%
cases:30.91%
controls:6.73%
cases:18.18%
controls:0.00%
cases:29.09%
controls:8.01%
—
—
—
—
26
250
29
300
28
220
27
330
17
37
38
513
10
0
45
550
16
44
39
505
—
—
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
8.0e-02
4.4e-01
1.8e+00
1.0e+50
1.5e+00
—
—
cases:47.27%
controls:45.27%
cases:50.91%
controls:40.00%
cases:30.91%
controls:6.73%
cases:18.18%
controls:0.00%
cases:29.09%
controls:8.01%
—
—
—
—
26
249
29
301
28
220
27
330
17
37
38
513
10
0
45
550
16
44
39
505
—
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
8.0e-02
4.4e-01
1.8e+00
1.0e+50
1.5e+00
—
—
cases:47.27%
controls:45.27%
cases:50.91%
controls:40.00%
cases:30.91%
controls:6.73%
cases:18.18%
controls:0.00%
cases:29.09%
controls:8.01%
—
—
—
—
26
249
29
301
28
220
27
330
17
37
38
513
10
0
45
550
16
44
39
505
—
—
MCH [Entitic mass]
28539-5 [3035941]
8.8e-02
4.6e-01
1.8e+00
1.0e+50
1.5e+00
—
—
cases:47.27%
controls:45.09%
cases:50.91%
controls:39.64%
cases:30.91%
controls:6.73%
cases:18.18%
controls:0.00%
cases:29.09%
controls:8.01%
—
—
—
—
26
248
29
302
28
218
27
332
17
37
38
513
10
0
45
550
16
44
39
505
—
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
4.4e-01
4.3e-01
1.5e+00
1.0e+50
1.8e+00
—
—
cases:40.00%
controls:30.00%
cases:34.55%
controls:25.64%
cases:18.18%
controls:4.55%
cases:14.55%
controls:0.00%
cases:20.00%
controls:4.01%
—
—
—
—
22
165
33
385
19
141
36
409
10
25
45
525
8
0
47
550
11
22
44
527
—
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.5e-01
4.0e-01
1.5e+00
1.0e+50
1.8e+00
—
—
cases:47.27%
controls:38.73%
cases:40.00%
controls:30.91%
cases:20.00%
controls:5.27%
cases:16.36%
controls:0.00%
cases:21.82%
controls:4.55%
—
—
—
—
26
213
29
337
22
170
33
380
11
29
44
521
9
0
46
550
12
25
43
524
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.3e-01
4.9e-01
1.5e+00
1.0e+50
1.8e+00
—
—
cases:47.27%
controls:39.09%
cases:41.82%
controls:30.55%
cases:20.00%
controls:5.27%
cases:12.73%
controls:0.00%
cases:21.82%
controls:4.55%
—
—
—
—
26
215
29
335
23
168
32
382
11
29
44
521
7
0
48
550
12
25
43
524
—
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.6e-01
3.1e-01
1.5e+00
1.0e+50
1.6e+00
—
—
cases:45.45%
controls:41.64%
cases:43.64%
controls:36.18%
cases:23.64%
controls:6.36%
cases:16.36%
controls:0.00%
cases:23.64%
controls:5.83%
—
—
—
—
25
229
30
321
24
199
31
351
13
35
42
515
9
0
46
550
13
32
42
517
—
—
CBC panel - Blood by Automated count
58410-2 [40761511]
-7.6e-02
-7.2e-02
1.7e+00
1.0e+50
1.4e+00
—
—
cases:38.18%
controls:40.00%
cases:27.27%
controls:28.73%
cases:20.00%
controls:4.36%
cases:9.09%
controls:0.00%
cases:20.00%
controls:6.01%
—
—
—
—
21
220
34
330
15
158
40
392
11
24
44
526
5
0
50
550
11
33
44
516
—
—
Laboratory Visit
OMOP4822461 [32036]
-3.6e-02
5.5e-01
1.7e+00
—
1.3e+00
—
—
cases:49.09%
controls:50.00%
cases:60.00%
controls:46.36%
cases:45.45%
controls:13.09%
—
—
cases:36.36%
controls:13.30%
—
—
—
—
27
275
28
275
33
255
22
295
25
72
30
478
—
20
73
35
476
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
-3.1e-01
6.1e-01
2.6e+00
—
1.8e+00
—
—
cases:9.09%
controls:12.00%
cases:16.36%
controls:9.64%
cases:10.91%
controls:0.91%
—
—
cases:12.73%
controls:2.37%
—
—
—
—
5
66
50
484
9
53
46
497
6
5
49
545
—
7
13
48
536
—
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.7e-01
3.0e-01
2.5e+00
—
—
—
—
cases:25.45%
controls:22.36%
cases:18.18%
controls:14.18%
cases:16.36%
controls:1.64%
—
—
—
—
—
—
—
—
14
123
41
427
10
78
45
472
9
9
46
541
—
—
—
—
Internal Medicine
11 [38004456]
7.4e-01
1.2e+00
—
1.0e+50
2.4e+00
—
—
cases:32.73%
controls:18.91%
cases:20.00%
controls:7.27%
—
—
cases:25.45%
controls:0.00%
cases:10.91%
controls:1.09%
—
—
—
—
18
104
37
446
11
40
44
510
—
14
0
41
550
6
6
49
543
—
—
Essential (primary) hypertension
I10 [45591453]
7.4e-01
7.3e-01
—
1.0e+50
2.4e+00
—
—
cases:29.09%
controls:16.36%
cases:18.18%
controls:9.64%
—
—
cases:14.55%
controls:0.00%
cases:9.09%
controls:0.91%
—
—
—
—
16
90
39
460
10
53
45
497
—
8
0
47
550
5
5
50
544
—
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
7.7e-01
2.3e+00
—
1.0e+50
—
—
—
cases:21.82%
controls:11.45%
cases:34.55%
controls:5.09%
—
—
cases:16.36%
controls:0.00%
—
—
—
—
—
—
12
63
43
487
19
28
36
522
—
9
0
46
550
—
—
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
-7.3e-02
1.2e+00
—
—
2.1e+00
—
—
cases:10.91%
controls:11.64%
cases:20.00%
controls:7.27%
—
—
—
—
cases:10.91%
controls:1.46%
—
—
—
—
6
64
49
486
11
40
44
510
—
—
6
8
49
541
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
-2.4e-01
1.3e+00
—
—
2.1e+00
—
—
cases:9.09%
controls:11.27%
cases:21.82%
controls:7.27%
—
—
—
—
cases:10.91%
controls:1.46%
—
—
—
—
5
62
50
488
12
40
43
510
—
—
6
8
49
541
—
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
6.7e-01
1.9e+00
—
—
—
—
—
cases:14.55%
controls:8.00%
cases:16.36%
controls:2.73%
—
—
—
—
—
—
—
—
—
—
8
44
47
506
9
15
46
535
—
—
—
—
—
isosorbide mononitrate; oral
C01DA14 [21600324]
1.9e+00
1.5e+00
-1.0e+50
—
—
—
—
cases:14.55%
controls:2.55%
cases:10.91%
controls:2.55%
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
8
14
47
536
6
14
49
536
0
6
55
544
—
—
—
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
3.0e-01
1.7e+00
—
—
—
—
—
cases:21.82%
controls:17.09%
cases:29.09%
controls:6.73%
—
—
—
—
—
—
—
—
—
—
12
94
43
456
16
37
39
513
—
—
—
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
—
1.7e+00
—
—
—
—
—
—
—
cases:14.55%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
—
8
16
47
534
—
—
—
—
—
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
1.7e+00
—
—
—
—
—
—
cases:14.55%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
—
—
8
16
47
534
—
—
—
—
—
—
Outpatient Visit
OP [9202]
1.1e-01
3.5e-01
2.1e-01
—
1.5e+00
—
—
cases:74.55%
controls:72.36%
cases:60.00%
controls:51.45%
cases:12.73%
controls:10.55%
—
—
cases:27.27%
controls:8.01%
—
—
—
—
41
398
14
152
33
283
22
267
7
58
48
492
—
15
44
40
505
—
—
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Screening procedure
SPAT1324 [2001700425]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
55
541
—
—
—
—
—
—
levofloxacin
S01AE05 [43534860]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
salbutamol; inhalant
R03AC02 [21603256]
-1.4e-01
4.8e-01
—
—
—
—
—
cases:12.73%
controls:14.36%
cases:9.09%
controls:5.82%
—
—
—
—
—
—
—
—
—
—
7
79
48
471
5
32
50
518
—
—
—
—
—
Spinalanesthesia
WX320 [2001310799]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
1.1e+00
—
—
—
—
—
—
cases:9.09%
controls:3.27%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
50
532
—
—
—
—
—
—
nepafenac
S01BC10 [21603648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
Feeling anxious/nervous/tense
P01 [2002000798]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
55
532
—
—
—
—
—
—
digoxin; oral, parenteral
C01AA05 [21600234]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
cefalexin; oral
J01DB01 [21602870]
-1.6e-01
—
-1.0e+50
—
—
—
—
cases:25.45%
controls:28.55%
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
14
157
41
393
—
0
5
55
545
—
—
—
—
Hypothyroidism/myxoedema
T86 [2002001128]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
Neurosurgery
14 [38004459]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
allopurinol; oral, parenteral
M04AA01 [21604131]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
—
0
12
55
538
—
—
—
—
—
calcium (different salts in combination); oral
A12AA20 [21600872]
-2.4e-01
—
-1.0e+50
—
—
—
—
cases:9.09%
controls:11.27%
—
—
cases:0.00%
controls:2.36%
—
—
—
—
—
—
—
—
5
62
50
488
—
0
13
55
537
—
—
—
—
Nonallergic asthma
J45.1 [45557625]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
1.2e+00
—
—
—
—
—
—
cases:10.91%
controls:3.64%
—
—
—
—
—
—
—
—
—
—
—
—
6
20
49
530
—
—
—
—
—
—
Diabetes, insulin-treated
103 [2001600103]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
20
55
530
—
—
—
—
—
—
Body mass index
60621009 [4245997]
-1.4e-01
-1.0e+50
—
—
—
—
—
cases:21.82%
controls:24.36%
cases:0.00%
controls:8.00%
—
—
—
—
—
—
—
—
—
—
12
134
43
416
0
44
55
506
—
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
7.0e-01
—
1.0e+50
—
—
—
—
cases:9.09%
controls:4.73%
—
—
cases:9.09%
controls:0.00%
—
—
—
—
—
—
—
—
5
26
50
524
—
5
0
50
550
—
—
—
—
cyproterone and estrogen
G03HB01 [21602617]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Preventive oral health care, short
SCA01 [2001310302]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.00%
cases:0.00%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
0
11
55
539
0
12
55
538
—
—
—
—
—
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.5e+00
—
—
—
—
—
—
cases:12.73%
controls:3.09%
—
—
—
—
—
—
—
—
—
—
—
—
7
17
48
533
—
—
—
—
—
—
Atrial fibrillation and atrial flutter, unspecified
I48.9 [45755409]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
Cardiac arrhythmia NOS
K80 [2002000607]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
General anesthesia, balanced
WX408 [2001310808]
9.7e-01
-1.0e+50
—
—
—
—
—
cases:9.09%
controls:3.64%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
5
20
50
530
0
5
55
545
—
—
—
—
—
Amphetamines [Presence] in Urine
3349-8 [3027944]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
Caries limited to enamel
K02.0 [45576967]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.00%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
11
55
539
0
5
55
545
—
—
—
—
—
Psoriasis vulgaris
L40.0 [45543370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
pH of Urine
2756-5 [3015736]
2.9e-01
5.5e-01
—
—
—
—
—
cases:10.91%
controls:8.36%
cases:9.09%
controls:5.45%
—
—
—
—
—
—
—
—
—
—
6
46
49
504
5
30
50
520
—
—
—
—
—
Hemoglobin [Mass/volume] in Capillary blood
30352-9 [3006184]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
False labour before 37 completed weeks of gestation
O47.0 [45582556]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Musculoskeletal sympt/complt other
L29 [2002000648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Periodontal treatment by dental hygienist
SDE02 [2001310350]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
20
55
530
—
—
—
—
—
—
tadalafil; oral
G04BE08 [21602653]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.00%
—
—
—
—
—
—
—
—
—
—
—
0
11
55
539
—
—
—
—
—
insulin glargine; parenteral
A10AE04 [21600739]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
55
537
—
—
—
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
55
537
—
—
—
—
—
—
Feeling depressed
P03 [2002000800]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Morphology ultrasound screening, weeks 18+0 to 21+6 of gestation
MA5AE [2001306841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Excision of other lesion extending through all layers of skin of trunk
QBE10 [2001309853]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Caries of dentine
K02.1 [45548134]
-2.7e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:14.55%
controls:18.18%
—
—
cases:0.00%
controls:1.45%
—
—
cases:0.00%
controls:1.28%
—
—
—
—
8
100
47
450
—
0
8
55
542
—
0
7
55
542
—
—
salmeterol and fluticasone
R03AK06 [21603280]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
Swollen ankles/oedema
K07 [2002000550]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
2.6e-01
-1.0e+50
—
—
—
—
—
cases:14.55%
controls:11.64%
cases:0.00%
controls:4.18%
—
—
—
—
—
—
—
—
—
—
8
64
47
486
0
23
55
527
—
—
—
—
—
chloramphenicol
D10AF03 [21602307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
Other and unspecified abdominal pain
R10.4 [45568113]
1.5e+00
—
—
—
—
—
—
cases:16.36%
controls:4.18%
—
—
—
—
—
—
—
—
—
—
—
—
9
23
46
527
—
—
—
—
—
—
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
—
1.1e+00
—
—
1.9e+00
—
—
—
—
cases:18.18%
controls:7.09%
—
—
—
—
cases:9.09%
controls:1.46%
—
—
—
—
—
10
39
45
511
—
—
5
8
50
541
—
—
Chronic ischaemic heart disease
I25 [45581765]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
55
541
—
—
—
—
—
—
Periodontal treatment, very brief
SDA01 [2001310326]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
9.7e-01
1.1e+00
-1.0e+50
—
—
—
—
cases:16.36%
controls:6.91%
cases:10.91%
controls:4.00%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
9
38
46
512
6
22
49
528
0
5
55
545
—
—
—
—
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
3.2e-01
—
—
—
—
—
—
cases:10.91%
controls:8.18%
—
—
—
—
—
—
—
—
—
—
—
—
6
45
49
505
—
—
—
—
—
—
General Practice
1 [38004446]
8.5e-01
1.1e+00
—
—
—
—
—
cases:25.45%
controls:12.73%
cases:10.91%
controls:4.00%
—
—
—
—
—
—
—
—
—
—
14
70
41
480
6
22
49
528
—
—
—
—
—
General health counselling
SPAT1312 [2001700413]
1.6e-01
—
—
—
—
—
—
cases:9.09%
controls:7.82%
—
—
—
—
—
—
—
—
—
—
—
—
5
43
50
507
—
—
—
—
—
—
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.64%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
9
55
541
0
5
55
545
—
—
—
—
—
clindamycin; vaginal
G01AA10 [21602372]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
55
539
—
—
—
—
—
—
atorvastatin; oral
C10AA05 [21601860]
2.5e-01
6.8e-02
—
—
—
—
—
cases:12.73%
controls:10.18%
cases:9.09%
controls:8.55%
—
—
—
—
—
—
—
—
—
—
7
56
48
494
5
47
50
503
—
—
—
—
—
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
betamethasone
D07AC01 [21602120]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
0
7
55
542
—
—
Neurology
13 [38004458]
2.2e-01
—
—
—
—
—
—
cases:10.91%
controls:8.91%
—
—
—
—
—
—
—
—
—
—
—
—
6
49
49
501
—
—
—
—
—
—
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.7e-01
5.2e-01
—
—
—
—
—
cases:14.55%
controls:12.55%
cases:12.73%
controls:8.00%
—
—
—
—
—
—
—
—
—
—
8
69
47
481
7
44
48
506
—
—
—
—
—
Swelling
A08 [2002000149]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
FEV1
20150-9 [3024653]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
Primary coxarthrosis, bilateral
M16.0 [45543482]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
dexamethasone and antiinfectives
S01CA01 [21603652]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
55
538
—
—
—
—
—
—
Result test/procedure
-60 [2002000131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
—
2.0e+00
—
—
—
—
—
—
—
cases:10.91%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
6
9
49
541
—
—
—
—
—
Cannabinoids [Presence] in Urine
3427-2 [3028300]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
Depressive disorder
P76 [2002000870]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
clopidogrel; oral
B01AC04 [21600989]
1.6e+00
—
—
—
—
—
—
cases:9.09%
controls:2.00%
—
—
—
—
—
—
—
—
—
—
—
—
5
11
50
539
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
7.4e-01
—
—
—
—
—
—
cases:9.09%
controls:4.55%
—
—
—
—
—
—
—
—
—
—
—
—
5
25
50
525
—
—
—
—
—
—
naproxen; oral, rectal
M01AE02 [21603968]
3.1e-01
—
—
—
—
—
—
cases:12.73%
controls:9.64%
—
—
—
—
—
—
—
—
—
—
—
—
7
53
48
497
—
—
—
—
—
—
Cough
R05 [2002000886]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
Photography of fundus of eye
XCK10 [2001301381]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
55
541
—
—
—
—
—
—
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
dexamethasone and antiinfectives
S03CA01 [21605206]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
55
536
—
—
—
—
—
—
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
55
534
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:4.18%
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
0
23
55
527
0
9
55
541
—
—
—
—
—
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
pH of Capillary blood
2745-8 [3009343]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
Other complicated root filling
SGB30 [2001310390]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Pure hypercholesterolaemia
E78.0 [45542771]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.82%
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
0
10
55
540
0
9
55
541
—
—
—
—
—
enalapril; oral, parenteral
C09AA02 [21601786]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
0
6
55
543
—
—
Iron deficiency anaemia
B80 [2002000291]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Pain in thoracic spine
M54.6 [45606247]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Alzheimer disease with late onset
G30.1 [45552521]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Dizziness and giddiness
R42 [45568132]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:4.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
24
55
526
—
—
—
—
—
—
Skin symptom/complaint other
S29 [2002000993]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
6.5e-01
7.1e-01
—
—
1.4e+00
—
—
cases:25.45%
controls:15.09%
cases:18.18%
controls:9.82%
—
—
—
—
cases:10.91%
controls:2.91%
—
—
—
—
14
83
41
467
10
54
45
496
—
—
6
16
49
533
—
—
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
—
1.1e+00
—
—
2.0e+00
—
—
—
—
cases:20.00%
controls:7.82%
—
—
—
—
cases:9.09%
controls:1.28%
—
—
—
—
—
11
43
44
507
—
—
5
7
50
542
—
—
Retention of urine
R33 [45587507]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.64%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
9
55
541
0
5
55
545
—
—
—
—
—
Mouth breathing
R06.5 [45573006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Recording of ECG
SPAT1097 [2001700198]
1.1e+00
—
—
—
—
—
—
cases:9.09%
controls:3.09%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
50
533
—
—
—
—
—
—
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Student oral health check consistent with decree to assess need for oral health guidance and services
WYA50 [2001310877]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
—
1.3e+00
—
—
—
—
—
—
—
cases:10.91%
controls:3.27%
—
—
—
—
—
—
—
—
—
—
—
6
18
49
532
—
—
—
—
—
Orthopedic Surgery
20 [38004465]
-1.9e-01
—
—
—
-1.0e+50
—
—
cases:14.55%
controls:17.09%
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
8
94
47
456
—
—
—
0
6
55
543
—
—
Carboxyhemoglobin/Hemoglobin.total in Blood
20563-3 [3023081]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Need for immunization against other specified single viral diseases
Z25.8 [45547296]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.45%
cases:0.00%
controls:1.45%
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
0
8
55
542
0
8
55
542
—
—
0
5
55
544
—
—
tizanidine; oral
M03BX02 [21604116]
1.2e-01
—
—
—
—
—
—
cases:9.09%
controls:8.18%
—
—
—
—
—
—
—
—
—
—
—
—
5
45
50
505
—
—
—
—
—
—
Gastroenterology
10 [38004455]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:16.36%
controls:0.00%
—
—
—
—
—
—
—
—
—
9
0
46
550
—
—
—
Rotator cuff syndrome
M75.1 [45596678]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
7.5e-01
—
—
—
—
—
—
cases:10.91%
controls:5.45%
—
—
—
—
—
—
—
—
—
—
—
—
6
30
49
520
—
—
—
—
—
—
FEV1 percent change
69983-5 [42868472]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
alfuzosin; oral
G04CA01 [21602668]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
6.8e-02
9.8e-01
—
—
—
—
—
cases:9.09%
controls:8.55%
cases:10.91%
controls:4.36%
—
—
—
—
—
—
—
—
—
—
5
47
50
503
6
24
49
526
—
—
—
—
—
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
ibuprofen
R02AX02 [1588667]
-1.8e-01
-3.1e-01
—
—
—
—
—
cases:27.27%
controls:31.09%
cases:10.91%
controls:14.36%
—
—
—
—
—
—
—
—
—
—
15
171
40
379
6
79
49
471
—
—
—
—
—
mirabegron; oral
G04BD12 [43534790]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
Acute upper respiratory infection, unspecified
J06.9 [45562437]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.73%
—
—
—
—
—
—
—
—
—
—
—
0
15
55
535
—
—
—
—
—
Chest pain, unspecified
R07.4 [45558450]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
rivastigmine; oral, transdermal
N06DA03 [21604796]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
5
55
545
0
5
55
545
—
—
—
—
—
Application of soft bandage
SPAT1211 [2001700312]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
55
541
—
—
—
—
—
—
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Ambulatory ECG
XF404 [2001303370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Cocaine [Presence] in Urine
3397-7 [3016879]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
codeine and paracetamol
N02AJ06 [1123647]
-1.7e-01
—
—
—
—
—
—
cases:10.91%
controls:12.73%
—
—
—
—
—
—
—
—
—
—
—
—
6
70
49
480
—
—
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
—
9.4e-01
—
—
—
—
—
—
—
cases:10.91%
controls:4.55%
—
—
—
—
—
—
—
—
—
—
—
6
25
49
525
—
—
—
—
—
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
-1.6e-01
3.3e-02
—
—
—
—
—
cases:21.82%
controls:24.73%
cases:12.73%
controls:12.36%
—
—
—
—
—
—
—
—
—
—
12
136
43
414
7
68
48
482
—
—
—
—
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
2.2e-01
—
—
—
—
—
—
cases:9.09%
controls:7.45%
—
—
—
—
—
—
—
—
—
—
—
—
5
41
50
509
—
—
—
—
—
—
Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 [3037551]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Palpitations
R00.2 [45558446]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
dexamethasone
D07AB19 [21602116]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
Dyspnoea
R06.0 [45558449]
7.0e-01
—
—
—
—
—
—
cases:9.09%
controls:4.73%
—
—
—
—
—
—
—
—
—
—
—
—
5
26
50
524
—
—
—
—
—
—
losartan; oral
C09CA01 [21601824]
6.5e-01
—
—
—
—
—
—
cases:10.91%
controls:6.00%
—
—
—
—
—
—
—
—
—
—
—
—
6
33
49
517
—
—
—
—
—
—
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
55
537
—
—
—
—
—
—
Simple examination of mouth
SAA01 [2001310274]
-6.9e-02
-2.6e-01
-1.0e+50
—
—
—
—
cases:23.64%
controls:24.91%
cases:9.09%
controls:11.45%
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
13
137
42
413
5
63
50
487
0
6
55
544
—
—
—
—
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
-7.3e-02
9.4e-01
—
—
—
—
—
cases:10.91%
controls:11.64%
cases:10.91%
controls:4.55%
—
—
—
—
—
—
—
—
—
—
6
64
49
486
6
25
49
525
—
—
—
—
—
brimonidine
S01GA07 [947915]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Therapeutic discussion
SPAT1240 [2001700341]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
Disturbance of activity and attention
F90.0 [45542870]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
7
55
543
0
5
55
545
—
—
—
—
—
Unspecified fall
W19 [45756257]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
General Surgery
2 [38004447]
3.8e-01
7.0e-01
—
1.0e+50
—
—
—
cases:21.82%
controls:16.00%
cases:9.09%
controls:4.73%
—
—
cases:10.91%
controls:0.00%
—
—
—
—
—
—
12
88
43
462
5
26
50
524
—
6
0
49
550
—
—
—
Specific gravity of Urine by Refractometry
5810-7 [3019150]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:6.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
34
55
516
—
—
—
—
—
—
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
Treatment plan or consultation
WZC00 [2001310885]
7.9e-01
—
—
—
—
—
—
cases:12.73%
controls:6.18%
—
—
—
—
—
—
—
—
—
—
—
—
7
34
48
516
—
—
—
—
—
—
Arthritis, unspecified
M13.9 [45567463]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
—
8.3e-01
—
—
—
—
—
—
—
cases:9.09%
controls:4.18%
—
—
—
—
—
—
—
—
—
—
—
5
23
50
527
—
—
—
—
—
simvastatin; oral
C10AA01 [21601856]
-1.6e-02
-6.4e-02
—
—
—
—
—
cases:12.73%
controls:12.91%
cases:9.09%
controls:9.64%
—
—
—
—
—
—
—
—
—
—
7
71
48
479
5
53
50
497
—
—
—
—
—
Pharmacy visit
OMOP4822462 [581458]
-3.2e-01
5.2e-01
5.5e-01
—
5.5e-01
—
—
cases:89.09%
controls:91.82%
cases:89.09%
controls:82.91%
cases:63.64%
controls:50.36%
—
—
cases:56.36%
controls:42.62%
—
—
—
—
49
505
6
45
49
456
6
94
35
277
20
273
—
31
234
24
315
—
—
insulin lispro; parenteral
A10AC04 [21600726]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.09%
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
0
6
55
544
0
8
55
542
—
—
—
—
—
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
55
538
—
—
—
—
—
—
Foot and toes X-ray examination
NH3AA [2001308267]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
55
537
—
—
—
—
—
—
Other hypothyroidism
E03 [45581337]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
insulin lispro; parenteral
A10AB04 [21600718]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.09%
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
0
6
55
544
0
8
55
542
—
—
—
—
—
Cellulitis of finger and toe
L03.0 [45557691]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
Gas panel - Arterial blood
24336-0 [3019060]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
55
541
—
—
—
—
—
—
Glucose tolerance 2 hours gestational panel - Serum or Plasma
81324-6 [21492888]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
Observation for suspected nervous system disorder
Z03.3 [45609903]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
2.4e-01
—
—
—
—
—
—
cases:9.09%
controls:7.27%
—
—
—
—
—
—
—
—
—
—
—
—
5
40
50
510
—
—
—
—
—
—
Chronic apical periodontitis
K04.5 [45586691]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
Obstetrics / Gynecology
16 [38004461]
5.7e-02
8.7e-01
-1.0e+50
—
—
—
—
cases:10.91%
controls:10.36%
cases:9.09%
controls:4.00%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
6
57
49
493
5
22
50
528
0
5
55
545
—
—
—
—
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Infiltration anesthesia
WX110 [2001310767]
-1.2e-01
—
—
—
—
—
—
cases:20.00%
controls:22.00%
—
—
—
—
—
—
—
—
—
—
—
—
11
121
44
429
—
—
—
—
—
—
Cardiology
6 [38004451]
5.7e-01
—
-1.0e+50
—
—
—
—
cases:20.00%
controls:12.36%
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
11
68
44
482
—
0
6
55
544
—
—
—
—
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
55
536
—
—
—
—
—
—
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:4.18%
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
0
23
55
527
0
9
55
541
—
—
—
—
—
candesartan and diuretics
C09DA06 [21601838]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
Combined first trimester screening
MA3AE [2001306839]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
etoricoxib; oral
M01AH05 [21603996]
4.5e-02
—
—
—
—
—
—
cases:14.55%
controls:14.00%
—
—
—
—
—
—
—
—
—
—
—
—
8
77
47
473
—
—
—
—
—
—
Sexual health counselling
SPAT1308 [2001700409]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
55
541
—
—
—
—
—
—
Gas panel - Capillary blood
24337-8 [3022313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Congestive heart failure
I50.0 [45567179]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
combinations of corticosteroids
D07AB30 [21602118]
-1.1e-01
6.6e-01
—
—
-1.0e+50
—
—
cases:10.91%
controls:12.00%
cases:9.09%
controls:4.91%
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
6
66
49
484
5
27
50
523
—
—
0
6
55
543
—
—
Restricted oral and dental health check by dental hygienist or dental assistant
SAB01 [2001310279]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Surveillance of contraceptive drugs
Z30.4 [45547299]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
hydrocortisone; oral, parenteral
H02AB09 [21602737]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
Gonarthrosis [arthrosis of knee]
M17 [45601350]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
betamethasone
S02BA07 [21605169]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
0
7
55
542
—
—
dexamethasone
D10AA03 [21602286]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
ramipril; oral
C09AA05 [21601789]
8.3e-01
1.1e+00
—
—
-1.0e+50
—
—
cases:14.55%
controls:6.91%
cases:12.73%
controls:4.55%
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
8
38
47
512
7
25
48
525
—
—
0
9
55
540
—
—
Tension-type headache
G44.2 [45581495]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Hospital outpatient
ZY010 [2001311599]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
2.4e-01
-4.8e-01
1.4e+00
—
—
—
—
cases:38.18%
controls:32.73%
cases:12.73%
controls:19.09%
cases:9.09%
controls:2.36%
—
—
—
—
—
—
—
—
21
180
34
370
7
105
48
445
5
13
50
537
—
—
—
—
methotrexate; oral, parenteral
L04AX03 [21603929]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.82%
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
0
10
55
540
0
6
55
544
—
—
—
—
—
memantine; oral
N06DX01 [21604799]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:1.09%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
0
5
55
545
0
6
55
544
0
5
55
545
—
—
—
—
Other seropositive rheumatoid arthritis
M05.8 [45538634]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.64%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
9
55
541
0
5
55
545
—
—
—
—
—
bisoprolol; oral
C07AB07 [21601689]
6.6e-01
5.7e-01
1.3e+00
—
1.1e+00
—
—
cases:29.09%
controls:17.45%
cases:23.64%
controls:14.91%
cases:10.91%
controls:3.09%
—
—
cases:12.73%
controls:4.74%
—
—
—
—
16
96
39
454
13
82
42
468
6
17
49
533
—
7
26
48
523
—
—
Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
32046-5 [3021584]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Extended examination of mouth
SAA03 [2001310276]
4.5e-02
—
—
—
—
—
—
cases:9.09%
controls:8.73%
—
—
—
—
—
—
—
—
—
—
—
—
5
48
50
502
—
—
—
—
—
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
—
—
1.0e+50
—
—
—
—
—
—
—
—
cases:14.55%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
8
0
47
550
—
—
—
—
naproxen and esomeprazole; oral
M01AE52 [40254096]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
Bacteria [Presence] in Urine
87829-8 [36304419]
—
1.2e+00
—
—
—
—
—
—
—
cases:9.09%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
—
5
16
50
534
—
—
—
—
—
Oncology Clinic/Center
261QX0200X [38004268]
4.2e-01
—
—
—
—
—
—
cases:9.09%
controls:6.18%
—
—
—
—
—
—
—
—
—
—
—
—
5
34
50
516
—
—
—
—
—
—
warfarin; oral, parenteral
B01AA03 [21600965]
1.2e+00
9.4e-01
—
—
—
—
—
cases:16.36%
controls:5.45%
cases:10.91%
controls:4.55%
—
—
—
—
—
—
—
—
—
—
9
30
46
520
6
25
49
525
—
—
—
—
—
naproxcinod
M01AE18 [40254094]
3.1e-01
—
—
—
—
—
—
cases:12.73%
controls:9.64%
—
—
—
—
—
—
—
—
—
—
—
—
7
53
48
497
—
—
—
—
—
—
Insect bite/sting
S12 [2002000977]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
55
536
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
6.7e-02
1.0e+00
—
—
—
—
—
cases:12.73%
controls:12.00%
cases:12.73%
controls:5.09%
—
—
—
—
—
—
—
—
—
—
7
66
48
484
7
28
48
522
—
—
—
—
—
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:3.09%
—
—
—
—
—
—
—
—
—
—
—
0
17
55
533
—
—
—
—
—
Office Visit
OMOP4822458 [581477]
9.4e-01
—
—
—
—
—
—
cases:16.36%
controls:7.09%
—
—
—
—
—
—
—
—
—
—
—
—
9
39
46
511
—
—
—
—
—
—
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
1.2e+00
1.7e+00
—
—
—
—
—
cases:12.73%
controls:4.00%
cases:10.91%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
7
22
48
528
6
12
49
538
—
—
—
—
—
Other specified special examinations
Z01.8 [45581003]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
Chronic hypertension
205 [2001600203]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
Creatine kinase.MB [Mass/volume] in Serum or Plasma
13969-1 [3005785]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
perindopril; oral
C09AA04 [21601788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
Intraoral radiographic dental examination
EB1AA [2001301903]
-1.9e-01
—
—
—
—
—
—
cases:10.91%
controls:12.91%
—
—
—
—
—
—
—
—
—
—
—
—
6
71
49
479
—
—
—
—
—
—
empagliflozin; oral
A10BK03 [1123740]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
0
5
55
545
0
6
55
544
—
—
—
—
—
Mitochondria Ab [Titer] in Serum
20483-4 [3034770]
—
—
1.0e+50
—
—
—
—
—
—
—
—
cases:16.36%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
9
0
46
550
—
—
—
—
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
20
55
530
—
—
—
—
—
—
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
7
55
543
0
5
55
545
—
—
—
—
—
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
-2.2e-01
4.8e-01
—
—
—
—
—
cases:9.09%
controls:11.09%
cases:9.09%
controls:5.82%
—
—
—
—
—
—
—
—
—
—
5
61
50
489
5
32
50
518
—
—
—
—
—
Anion gap in Blood by calculation
41276-7 [3039000]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Nonorganic insomnia
F51.0 [45552492]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
fenoterol and ipratropium bromide
R03AL01 [43534843]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
phenoxymethylpenicillin; oral
J01CE02 [21602842]
2.6e-01
-1.0e+50
—
—
—
—
—
cases:14.55%
controls:11.64%
cases:0.00%
controls:4.18%
—
—
—
—
—
—
—
—
—
—
8
64
47
486
0
23
55
527
—
—
—
—
—
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
55
542
—
—
—
—
—
—
epinephrine
S01EA01 [21603673]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
5
55
545
0
5
55
545
—
—
—
—
—
Pap smear
SPAT1193 [2001700294]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
Home Visit
OMOP4822459 [581476]
9.2e-01
—
—
—
1.7e+00
—
—
cases:14.55%
controls:6.36%
—
—
—
—
—
—
cases:9.09%
controls:1.82%
—
—
—
—
8
35
47
515
—
—
—
5
10
50
539
—
—
desonide
D07AB08 [21602112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
55
536
—
—
—
—
—
—
tretinoin; ointment
D10AD01 [21602293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Albumin [Mass/volume] in Urine
1754-1 [3012516]
4.4e-01
—
—
—
—
—
—
cases:10.91%
controls:7.27%
—
—
—
—
—
—
—
—
—
—
—
—
6
40
49
510
—
—
—
—
—
—
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
-2.5e-02
-1.2e-02
—
—
—
—
—
cases:32.73%
controls:33.27%
cases:18.18%
controls:18.36%
—
—
—
—
—
—
—
—
—
—
18
183
37
367
10
101
45
449
—
—
—
—
—
vilanterol and fluticasone furoate
R03AK10 [43534841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
6.5e-01
1.4e+00
—
—
—
—
—
cases:10.91%
controls:6.00%
cases:9.09%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
6
33
49
517
5
13
50
537
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
7.0e-01
—
—
—
—
—
—
—
cases:9.09%
controls:4.73%
—
—
—
—
—
—
—
—
—
—
—
5
26
50
524
—
—
—
—
—
Health maint/preventive medicine
A98 [2002000231]
-2.2e-02
-2.0e-01
—
—
1.1e+00
—
—
cases:43.64%
controls:44.18%
cases:29.09%
controls:33.45%
—
—
—
—
cases:10.91%
controls:4.01%
—
—
—
—
24
243
31
307
16
184
39
366
—
—
6
22
49
527
—
—
Counselling, unspecified
Z71.9 [45561648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Treatment-related counselling outside office
SPAT1249 [2001700350]
4.7e-01
—
—
—
—
—
—
cases:16.36%
controls:10.91%
—
—
—
—
—
—
—
—
—
—
—
—
9
60
46
490
—
—
—
—
—
—
clindamycin
D10AF01 [21602305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
valsartan and diuretics
C09DA03 [21601836]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Knee symptom/complaint
L15 [2002000639]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:3.64%
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
0
20
55
530
0
9
55
541
—
—
—
—
—
brinzolamide
S01EC04 [21603696]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.00%
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
0
11
55
539
0
8
55
542
—
—
—
—
—
Retained molar with obstruction in the lower jaw
K01.17 [2000502662]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
hydroxychloroquine; oral
P01BA02 [21604889]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Laboratory test
15220000 [4034850]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
0
9
55
541
—
—
—
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
formoterol and beclometasone
R03AK08 [43534839]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.09%
cases:0.00%
controls:1.45%
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
0
6
55
544
0
8
55
542
—
—
0
5
55
544
—
—
Left side
ZXA05 [2001311347]
9.8e-01
—
—
—
—
—
—
cases:10.91%
controls:4.36%
—
—
—
—
—
—
—
—
—
—
—
—
6
24
49
526
—
—
—
—
—
—
Very demanding periodontal treatment
SDA05 [2001310330]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Pain localized to other parts of lower abdomen
R10.3 [45534426]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
55
536
—
—
—
—
—
—
Hip symptom/complaint
L13 [2002000637]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
other preparations, combinations; ointment
C05AX03 [21601631]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
Ultrasound examination of mammary glands
HA1AE [2001303886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
55
540
—
—
—
—
—
—
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
acitretin; oral
D05BB02 [21602051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
—
Complicated extraction of tooth
EBA05 [2001301924]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
0
6
55
544
—
—
—
—
—
Otolaryngology
4 [38004449]
3.7e-01
—
—
—
—
—
—
cases:14.55%
controls:10.55%
—
—
—
—
—
—
—
—
—
—
—
—
8
58
47
492
—
—
—
—
—
—
Sick sinus syndrome
I49.5 [45562354]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.55%
—
—
—
—
—
—
—
—
—
—
—
0
14
55
536
—
—
—
—
—
Other disorders of vitreous body
H43.8 [45533329]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
5
55
545
0
5
55
545
—
—
—
—
—
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
pH of Urine by Test strip
5803-2 [3022621]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.82%
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
0
10
55
540
0
8
55
542
—
—
—
—
—
clobetasol
D07AD01 [21602141]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
55
537
—
—
—
—
—
—
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
55
543
—
—
—
—
—
—
clidinium and psycholeptics
A03CA02 [21600204]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—
Endocrinology
46 [38004485]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
carbamide
D02AE01 [21601975]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
55
545
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
17
10
23.34
12.10
1.4
1.2
—
—
titre
—
0
0
7
5
15.63
4.70
1.0
1.0
1.58
1.42
g/l
—
7
5
18
66
3.50
4.23
1.3
1.5
—
—
—
0
0
25
114
3.10
4.12
1.5
1.4
1.73
2.31
g/l
1.15
18
68
36
211
2.86
3.65
22.9
10.9
1.35
1.21
inr
0.82
30
171
34
206
2.57
3.05
10.0
5.8
35.69
35.47
g/l
0.07
34
192
15
60
3.02
2.99
2.9
3.8
1.91
1.81
%
0.08
15
53
17
74
2.84
2.92
1.4
1.6
—
—
—
0
0
26
146
2.42
2.66
3.4
3.0
—
—
—
0
0
35
230
2.32
2.44
10.2
9.0
1.23
1.22
mmol/l
0.18
30
195
16
75
2.57
2.35
1.8
1.6
—
—
—
0
0
10
37
3.05
2.20
15.7
14.8
24.28
24.44
mmol/l
—
10
37
8
25
3.54
2.19
1.1
1.2
—
—
—
0
0
37
257
2.21
2.16
3.5
4.1
0.00
0.00
estimate
—
9
59
26
157
2.19
2.16
6.0
9.9
—
—
—
0
0
24
141
2.20
2.12
1.5
1.4
—
—
—
0
0
8
27
3.27
2.02
10.8
9.9
0.61
0.57
%
—
8
27
8
28
3.15
1.94
10.9
9.6
1.22
1.65
%
—
8
28
9
35
2.85
1.90
1.2
1.2
—
—
—
0
0
32
218
2.04
1.88
13.6
8.8
1.22
1.21
mmol/l
0.09
32
200
5
13
4.10
1.75
6.8
23.3
67.48
69.69
%
—
5
13
30
206
1.95
1.66
4.2
3.4
—
—
estimate
—
0
0
29
198
1.93
1.63
3.7
3.8
6.33
6.28
ph
0.09
18
107
14
73
2.21
1.60
13.4
8.4
104.21
104.97
mmol/l
0.23
14
73
38
286
1.95
1.57
9.6
14.3
3.69
3.93
e9/l
0.32
31
252
10
45
2.48
1.56
1.2
1.3
—
—
—
0
0
27
182
1.90
1.56
2.0
1.9
1.27
1.36
mmol/l
0.28
21
141
22
139
1.94
1.53
4.8
4.5
7.39
7.40
ph
0.76
13
97
35
259
1.89
1.50
5.9
9.0
0.17
0.19
e9/l
0.31
30
223
34
250
1.87
1.48
5.8
8.8
0.60
0.56
e9/l
0.43
29
215
35
260
1.87
1.47
3.5
4.1
0.00
0.00
estimate
—
9
57
26
177
1.85
1.43
3.2
4.2
9.01
42.79
e6/l
1.62
17
132
34
252
1.84
1.42
5.8
8.8
0.04
0.04
e9/l
0.21
29
214
20
127
1.88
1.35
4.7
4.7
—
—
—
0
0
35
265
1.81
1.34
3.5
4.1
0.00
0.00
estimate
—
9
55
25
172
1.80
1.31
2.2
2.0
—
—
—
0
0
8
36
2.41
1.30
1.8
1.5
—
—
—
0
0
20
129
1.84
1.28
3.6
3.7
5.79
12.78
mg/mmol
0.56
13
71
11
57
2.15
1.27
1.6
1.2
—
—
—
0
0
5
19
2.78
1.24
2.0
1.8
—
—
—
0
0
10
51
2.16
1.19
14.8
8.5
2.19
0.91
mmol/l
—
10
41
23
159
1.74
1.16
2.4
3.4
19.27
416.81
e6/l
0.52
17
129
19
126
1.76
1.09
2.9
2.9
41.01
56.08
mg/l
0.24
13
69
10
53
2.07
1.09
14.8
9.3
7.40
7.39
ph
—
5
27
20
135
1.73
1.08
2.5
3.3
—
—
estimate
—
0
0
33
259
1.64
1.00
6.0
8.7
1.81
1.74
e9/l
0.18
28
227
24
174
1.65
0.99
4.8
3.4
31.42
33.95
ng/l
0.05
19
123
10
57
1.91
0.90
1.1
1.6
—
—
—
0
0
20
142
1.62
0.88
2.6
3.2
0.10
0.33
e6/l
0.99
14
111
18
125
1.64
0.86
6.9
6.8
—
—
—
0
0
8
47
1.81
0.85
20.5
11.9
—
—
—
0
0
52
471
2.00
0.82
23.6
15.3
25.51
23.36
mg/l
0.20
45
373
5
25
2.09
0.74
11.8
3.0
36.86
36.86
°c
—
5
25
7
41
1.80
0.73
1.1
1.5
—
—
—
0
0
7
42
1.76
0.71
14.7
9.7
24.47
23.41
mmol/l
—
7
42
52
480
1.80
0.70
25.3
13.9
—
—
—
0
0
25
197
1.47
0.67
2.6
1.9
74.84
93.83
pmol/l
1.20
11
95
18
137
1.46
0.56
3.4
2.7
—
—
—
0
0
28
232
1.40
0.55
15.7
16.0
0.00
0.06
e9/l
0.60
20
195
6
40
1.56
0.53
9.5
6.1
—
—
—
0
0
15
112
1.46
0.51
3.9
4.7
—
—
—
0
0
20
158
1.41
0.51
3.8
3.6
—
—
—
0
0
8
56
1.50
0.45
1.0
1.2
—
—
—
0
0
5
31
1.67
0.44
9.8
7.7
9.10
8.95
kpa
—
5
31
5
32
1.61
0.43
5.6
5.8
7.39
7.35
ph
—
5
21
0
16
0.00
0.42
0.0
1.5
—
0.89
—
0
16
25
211
1.32
0.41
3.7
3.8
0.00
0.00
estimate
—
7
50
5
35
1.47
0.40
16.4
11.7
97.04
93.37
%
—
5
35
23
194
1.31
0.38
2.8
3.1
—
—
—
0
0
6
45
1.37
0.35
4.5
4.7
1.27
1.22
mmol/l
—
6
38
7
51
1.42
0.33
1.7
1.4
—
—
—
0
0
18
150
1.29
0.31
3.3
4.4
0.00
0.00
estimate
—
8
54
18
152
1.27
0.28
3.3
3.1
0.00
0.00
estimate
—
7
48
5
37
1.38
0.24
16.4
11.1
1.10
1.72
%
—
5
37
0
11
0.00
0.21
0.0
4.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
11
90
1.27
0.21
1.5
2.0
—
—
—
0
0
13
109
1.25
0.21
3.5
4.5
1.02
1.02
kg/l
—
7
64
6
49
1.25
0.21
3.0
4.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
15497.11
—
0
9
7
59
1.21
0.19
1.1
1.5
—
—
—
0
0
16
143
1.16
0.13
6.6
6.4
—
—
—
0
0
44
424
1.16
0.12
5.1
5.0
2.48
1.96
mu/l
1.48
39
387
13
117
1.14
0.09
1.8
2.5
6.95
3.67
e6/l
0.47
13
102
42
407
1.12
0.08
31.0
20.1
14.00
13.63
%
0.47
42
401
0
6
0.00
0.00
0.0
12.0
—
7.50
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
20.7
—
712.00
—
0
6
0
6
0.00
0.00
0.0
1.3
—
5.10
—
0
6
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
170.86
—
0
7
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.6
—
340.38
—
0
8
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
66
0.90
-0.00
2.2
3.2
3.57
4.12
e9/l
—
6
58
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_PORBILIRNAS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have E4_PORBILIRNAS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: E4_PORBILIRNAS – Disorder of bilirubin metabolism, other/unspecified

GWS hits: 2

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data